RNAi technology

Roche Teams up with Alnylam for Antihypertensive Drug

Swiss pharmaceutical company Roche will collaborate with Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals to further develop its drug zilebesiran for the treatment of hypertension. The therapeutic, which is in Phase 2 clinical trials, uses the cellular mechanism RNA interference (RNAi) for targeted gene silencing.

News

Syngenta Pays Big Premium for Seed Firm Devgen

News

Seed Firm Devgen Signs Syngenta Pesticide Deal

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

From Lab to Market Challenge

Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.